Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany
Author:
Funder
Novartis Pharma
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00432-016-2209-1.pdf
Reference29 articles.
1. Antonioli E, Guglielmelli P, Pieri L, Finazzi M, Rumi E, Martinelli V et al (2012) Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol 87:552–554
2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
3. Barbui T, Thiele J, Vannucchi AM, Tefferi A (2015) Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J 5:e337
4. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC et al (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European leukemianet consensus conference. Blood 113:4829–4833
5. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H et al (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European leukemianet (ELN) consensus process. Br J Haematol 148:961–963
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study;Cancers;2023-07-21
2. Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice;eJHaem;2023-06-07
3. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany;Journal of Cancer Research and Clinical Oncology;2023-03-08
4. Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea;Cancer;2022-04-13
5. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera;Journal of Cancer Research and Clinical Oncology;2021-11-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3